(35.170.78.142)
Users online: 2022    [ij] [ij] [ij] 
Email id
 

Asian Journal of Research in Pharmaceutical Science
Year : 2018, Volume : 8, Issue : 2
First page : ( 68) Last page : ( 72)
Print ISSN : 2231-5640. Online ISSN : 2231-5659.
Article DOI : 10.5958/2231-5659.2018.00014.0

Polycystic Ovary Syndrome (PCOS): A Thief of Womenhood

Shoukath Usama1,*, Shoukath Umama2, Sultana Salma3, Uddin Mohammed Nayeem4

1II Year B. Pharmacy, Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India

2II Year, D. Pharmacy, kamala Nehru Polytechnic for Women, Exhibition Ground, Nampally, Hyderabad, Telangana, India

3III year, Pharm. D., Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India

4Asst. Professor, Department of Pharmacology and Pharmacy Practice, Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Yadadri (Dist)-508284, Telangana, India

*Corresponding Author E-mail: nayeemfarooqui2010@gmail.com

Online published on 7 July, 2018.

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women at reproductive age associated with reproductive and metabolic dysfunction. With prevalence ranging from 2.2% to 26% among the age group 18 to 45 years. It is characterized by oligo/anovulation, hyperandrogenism, and polycystic ovaries. Women with PCOS have higher rates of endometrial cancer, cardiovascular disease, dyslipidemia, and type-2 diabetes mellitus. The proposed Diagnostic Tools for Polycystic Ovary Syndrome as per Androgen Excess Society (AES) Criteria (2006) are Hyperandrogenism, Oligo-ovulation/anovulation, Polycystic ovaries, Exclusion of other related disorders. Treatment could be either pharmacological includes insulin therapy, anti androgens, or nonpharmacological includes diet control, weight loss, and exercise. The present review provides the readers knowledge about the polycystic ovarian syndrome.

Top

Keywords

Polycystic ovary, androgen, anovulation, infertility, LH, FSH.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
452,230,412 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.